B-Cell Non-Hodgkin Lymphoma-Pipeline Review, H2 2016

B-Cell Non-Hodgkin Lymphoma-Pipeline Review, H2 2016


  • Products Id :- GMDHC8609IDB
  • |
  • Pages: 1101
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Global Markets Direct’s, ‘B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2016’, provides an overview of the B-Cell Non-Hodgkin Lymphoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Non-Hodgkin Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Non-Hodgkin Lymphoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

 

Scope

 

The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma

The report reviews pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved B-Cell Non-Hodgkin Lymphoma therapeutics and enlists all their major and minor projects

The report assesses B-Cell Non-Hodgkin Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for B-Cell Non-Hodgkin Lymphoma

 

Reasons to Buy

 

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for B-Cell Non-Hodgkin Lymphoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding B-Cell Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 9

B-Cell Non-Hodgkin Lymphoma Overview 10

Therapeutics Development 11

B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies 13

B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes 24

B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance 26

B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies 30

B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes 60

B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development 62

B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment 191

Drug Profiles 229

B-Cell Non-Hodgkin Lymphoma - Dormant Projects 1042

B-Cell Non-Hodgkin Lymphoma - Discontinued Products 1056

B-Cell Non-Hodgkin Lymphoma - Product Development Milestones 1062

Appendix 1072

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H2 2016 39

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H2 2016 40

Number of Products under Development by Companies, H2 2016 41

Number of Products under Investigation by Universities/Institutes, H2 2016 52

Comparative Analysis by Late Stage Development, H2 2016 54

Comparative Analysis by Clinical Stage Development, H2 2016 55

Comparative Analysis by Early Stage Products, H2 2016 56

Assessment by Monotherapy Products, H2 2016 219

Assessment by Combination Products, H2 2016 220

Number of Products by Top 10 Targets, H2 2016 221

Number of Products by Stage and Top 10 Targets, H2 2016 221

Number of Products by Top 10 Mechanism of Actions, H2 2016 238

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 238

Number of Products by Routes of Administration, H2 2016 253

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 253

Number of Products by Top 10 Molecule Types, H2 2016 255

Number of Products by Stage and Top 10 Molecule Types, H2 2016 255

List of Tables

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma, H2 2016 39

Number of Products under Development for B-Cell Non-Hodgkin Lymphoma - Comparative Analysis, H2 2016 40

Number of Products under Development by Companies, H2 2016 42

Number of Products under Development by Companies, H2 2016 (Contd..1) 43

Number of Products under Development by Companies, H2 2016 (Contd..2) 44

Number of Products under Development by Companies, H2 2016 (Contd..3) 45

Number of Products under Development by Companies, H2 2016 (Contd..4) 46

Number of Products under Development by Companies, H2 2016 (Contd..5) 47

Number of Products under Development by Companies, H2 2016 (Contd..6) 48

Number of Products under Development by Companies, H2 2016 (Contd..7) 49

Number of Products under Development by Companies, H2 2016 (Contd..8) 50

Number of Products under Development by Companies, H2 2016 (Contd..9) 51

Number of Products under Investigation by Universities/Institutes, H2 2016 53

Comparative Analysis by Late Stage Development, H2 2016 54

Comparative Analysis by Clinical Stage Development, H2 2016 55

Comparative Analysis by Early Stage Development, H2 2016 56

Comparative Analysis by Unknown Stage Development, H2 2016 57

Products under Development by Companies, H2 2016 58

Products under Development by Companies, H2 2016 (Contd..1) 59

Products under Development by Companies, H2 2016 (Contd..2) 60

Products under Development by Companies, H2 2016 (Contd..3) 61

Products under Development by Companies, H2 2016 (Contd..4) 62

Products under Development by Companies, H2 2016 (Contd..5) 63

Products under Development by Companies, H2 2016 (Contd..6) 64

Products under Development by Companies, H2 2016 (Contd..7) 65

Products under Development by Companies, H2 2016 (Contd..8) 66

Products under Development by Companies, H2 2016 (Contd..9) 67

Products under Development by Companies, H2 2016 (Contd..10) 68

Products under Development by Companies, H2 2016 (Contd..11) 69

Products under Development by Companies, H2 2016 (Contd..12) 70

Products under Development by Companies, H2 2016 (Contd..13) 71

Products under Development by Companies, H2 2016 (Contd..14) 72

Products under Development by Companies, H2 2016 (Contd..15) 73

Products under Development by Companies, H2 2016 (Contd..16) 74

Products under Development by Companies, H2 2016 (Contd..17) 75

Products under Development by Companies, H2 2016 (Contd..18) 76

Products under Development by Companies, H2 2016 (Contd..19) 77

Products under Development by Companies, H2 2016 (Contd..20) 78

Products under Development by Companies, H2 2016 (Contd..21) 79

Products under Development by Companies, H2 2016 (Contd..22) 80

Products under Development by Companies, H2 2016 (Contd..23) 81

Products under Development by Companies, H2 2016 (Contd..24) 82

Products under Development by Companies, H2 2016 (Contd..25) 83

Products under Development by Companies, H2 2016 (Contd..26) 84

Products under Development by Companies, H2 2016 (Contd..27) 85

Products under Development by Companies, H2 2016 (Contd..28) 86

Products under Development by Companies, H2 2016 (Contd..29) 87

Products under Investigation by Universities/Institutes, H2 2016 88

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 89

B-Cell Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc., H2 2016 90

B-Cell Non-Hodgkin Lymphoma - Pipeline by AB Science SA, H2 2016 91

B-Cell Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, H2 2016 92

B-Cell Non-Hodgkin Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016 93

B-Cell Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 94

B-Cell Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics Sarl, H2 2016 95

B-Cell Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH , H2 2016 96

B-Cell Non-Hodgkin Lymphoma - Pipeline by Altor BioScience Corporation, H2 2016 97

B-Cell Non-Hodgkin Lymphoma - Pipeline by Amgen Inc., H2 2016 98

B-Cell Non-Hodgkin Lymphoma - Pipeline by arGEN-X BV, H2 2016 99

B-Cell Non-Hodgkin Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016 100

B-Cell Non-Hodgkin Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H2 2016 101

B-Cell Non-Hodgkin Lymphoma - Pipeline by Arvinas, Inc., H2 2016 102

B-Cell Non-Hodgkin Lymphoma - Pipeline by Asana BioSciences, LLC, H2 2016 103

B-Cell Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc., H2 2016 104

B-Cell Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2016 105

B-Cell Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, H2 2016 106

B-Cell Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H2 2016 107

B-Cell Non-Hodgkin Lymphoma - Pipeline by Bayer AG, H2 2016 108

B-Cell Non-Hodgkin Lymphoma - Pipeline by BeiGene, Ltd., H2 2016 109

B-Cell Non-Hodgkin Lymphoma - Pipeline by Bio-Path Holdings, Inc., H2 2016 110

B-Cell Non-Hodgkin Lymphoma - Pipeline by Biocon Limited, H2 2016 111

B-Cell Non-Hodgkin Lymphoma - Pipeline by Biogen Inc, H2 2016 112

B-Cell Non-Hodgkin Lymphoma - Pipeline by Biogenomics Limited, H2 2016 113

B-Cell Non-Hodgkin Lymphoma - Pipeline by BioInvent International AB, H2 2016 114

B-Cell Non-Hodgkin Lymphoma - Pipeline by BioNTech AG, H2 2016 115

B-Cell Non-Hodgkin Lymphoma - Pipeline by Biothera Pharmaceutical Inc, H2 2016 116

B-Cell Non-Hodgkin Lymphoma - Pipeline by bluebird bio, Inc., H2 2016 117

B-Cell Non-Hodgkin Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016 118

B-Cell Non-Hodgkin Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016 119

B-Cell Non-Hodgkin Lymphoma - Pipeline by Calithera Biosciences, Inc., H2 2016 120

B-Cell Non-Hodgkin Lymphoma - Pipeline by Celgene Corporation, H2 2016 121

B-Cell Non-Hodgkin Lymphoma - Pipeline by Cell Medica Limited, H2 2016 122

B-Cell Non-Hodgkin Lymphoma - Pipeline by Cell>Point, L.L.C., H2 2016 123

B-Cell Non-Hodgkin Lymphoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 124

B-Cell Non-Hodgkin Lymphoma - Pipeline by Celltrion, Inc., H2 2016 125

B-Cell Non-Hodgkin Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 126

B-Cell Non-Hodgkin Lymphoma - Pipeline by Clevexel Pharma SA, H2 2016 127

B-Cell Non-Hodgkin Lymphoma - Pipeline by Coherus BioSciences, Inc., H2 2016 128

B-Cell Non-Hodgkin Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 129

B-Cell Non-Hodgkin Lymphoma - Pipeline by Cornerstone Pharmaceuticals, Inc., H2 2016 130

B-Cell Non-Hodgkin Lymphoma - Pipeline by CrystalGenomics, Inc., H2 2016 131

B-Cell Non-Hodgkin Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 132

B-Cell Non-Hodgkin Lymphoma - Pipeline by CTI BioPharma Corp., H2 2016 133

B-Cell Non-Hodgkin Lymphoma - Pipeline by Curis, Inc., H2 2016 134

B-Cell Non-Hodgkin Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 135

B-Cell Non-Hodgkin Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2016 136

B-Cell Non-Hodgkin Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H2 2016 137

B-Cell Non-Hodgkin Lymphoma - Pipeline by Eisai Co., Ltd., H2 2016 138

B-Cell Non-Hodgkin Lymphoma - Pipeline by Eli Lilly and Company, H2 2016 139

B-Cell Non-Hodgkin Lymphoma - Pipeline by EpiZyme, Inc., H2 2016 140

B-Cell Non-Hodgkin Lymphoma - Pipeline by Erytech Pharma SA, H2 2016 141

B-Cell Non-Hodgkin Lymphoma - Pipeline by Evotec AG, H2 2016 142

B-Cell Non-Hodgkin Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 143

B-Cell Non-Hodgkin Lymphoma - Pipeline by Genentech, Inc., H2 2016 144

B-Cell Non-Hodgkin Lymphoma - Pipeline by Genor BioPharma Co Ltd, H2 2016 145

B-Cell Non-Hodgkin Lymphoma - Pipeline by Genosco, H2 2016 146

B-Cell Non-Hodgkin Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016 147

B-Cell Non-Hodgkin Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016 148

B-Cell Non-Hodgkin Lymphoma - Pipeline by H3 Biomedicine Inc., H2 2016 149

B-Cell Non-Hodgkin Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2016 150

B-Cell Non-Hodgkin Lymphoma - Pipeline by IGF Oncology, LLC., H2 2016 151

B-Cell Non-Hodgkin Lymphoma - Pipeline by Immune Design Corp., H2 2016 152

B-Cell Non-Hodgkin Lymphoma - Pipeline by ImmunoGen, Inc., H2 2016 153

B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunomedics, Inc., H2 2016 154

B-Cell Non-Hodgkin Lymphoma - Pipeline by Immunovaccine, Inc., H2 2016 155

B-Cell Non-Hodgkin Lymphoma - Pipeline by Incyte Corporation, H2 2016 156

B-Cell Non-Hodgkin Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2016 157

B-Cell Non-Hodgkin Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2016 158

B-Cell Non-Hodgkin Lymphoma - Pipeline by Innovent Biologics, Inc., H2 2016 159

B-Cell Non-Hodgkin Lymphoma - Pipeline by JHL Biotech, Inc., H2 2016 160

B-Cell Non-Hodgkin Lymphoma - Pipeline by Johnson & Johnson, H2 2016 161

B-Cell Non-Hodgkin Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016 162

B-Cell Non-Hodgkin Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 163

B-Cell Non-Hodgkin Lymphoma - Pipeline by Kite Pharma Inc, H2 2016 164

B-Cell Non-Hodgkin Lymphoma - Pipeline by LFB S.A., H2 2016 165

B-Cell Non-Hodgkin Lymphoma - Pipeline by Mabion SA, H2 2016 166

B-Cell Non-Hodgkin Lymphoma - Pipeline by mAbxience S.A., H2 2016 167

B-Cell Non-Hodgkin Lymphoma - Pipeline by MacroGenics, Inc., H2 2016 168

B-Cell Non-Hodgkin Lymphoma - Pipeline by MedImmune, LLC, H2 2016 169

B-Cell Non-Hodgkin Lymphoma - Pipeline by Medivation, Inc., H2 2016 170

B-Cell Non-Hodgkin Lymphoma - Pipeline by MEI Pharma, Inc., H2 2016 171

B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck & Co., Inc., H2 2016 172

B-Cell Non-Hodgkin Lymphoma - Pipeline by Merck KGaA, H2 2016 173

B-Cell Non-Hodgkin Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 174

B-Cell Non-Hodgkin Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2016 175

B-Cell Non-Hodgkin Lymphoma - Pipeline by Molecular Templates Inc., H2 2016 176

B-Cell Non-Hodgkin Lymphoma - Pipeline by Molplex Ltd., H2 2016 177

B-Cell Non-Hodgkin Lymphoma - Pipeline by MorphoSys AG, H2 2016 178

B-Cell Non-Hodgkin Lymphoma - Pipeline by Neumedicines Inc., H2 2016 179

B-Cell Non-Hodgkin Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H2 2016 180

B-Cell Non-Hodgkin Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016 181

B-Cell Non-Hodgkin Lymphoma - Pipeline by Novartis AG, H2 2016 182

B-Cell Non-Hodgkin Lymphoma - Pipeline by NovImmune SA, H2 2016 183

B-Cell Non-Hodgkin Lymphoma - Pipeline by Onconova Therapeutics, Inc., H2 2016 184

B-Cell Non-Hodgkin Lymphoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016 185

B-Cell Non-Hodgkin Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 186

B-Cell Non-Hodgkin Lymphoma - Pipeline by OXIS International, Inc., H2 2016 187

B-Cell Non-Hodgkin Lymphoma - Pipeline by Patrys Limited, H2 2016 188

B-Cell Non-Hodgkin Lymphoma - Pipeline by Pfizer Inc., H2 2016 189

B-Cell Non-Hodgkin Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2016 190

B-Cell Non-Hodgkin Lymphoma - Pipeline by Philogen S.p.A., H2 2016 191

B-Cell Non-Hodgkin Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 192

B-Cell Non-Hodgkin Lymphoma - Pipeline by RedHill Biopharma Ltd., H2 2016 193

B-Cell Non-Hodgkin Lymphoma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 194

B-Cell Non-Hodgkin Lymphoma - Pipeline by Respiratorius AB, H2 2016 195

B-Cell Non-Hodgkin Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 196

B-Cell Non-Hodgkin Lymphoma - Pipeline by Sandoz International GmbH, H2 2016 197

B-Cell Non-Hodgkin Lymphoma - Pipeline by Sanofi, H2 2016 198

B-Cell Non-Hodgkin Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016 199

B-Cell Non-Hodgkin Lymphoma - Pipeline by Selvita S.A., H2 2016 200

B-Cell Non-Hodgkin Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 201

B-Cell Non-Hodgkin Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2016 202

B-Cell Non-Hodgkin Lymphoma - Pipeline by Simcere Pharmaceutical Group, H2 2016 203

B-Cell Non-Hodgkin Lymphoma - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 204

B-Cell Non-Hodgkin Lymphoma - Pipeline by Stemline Therapeutics, Inc., H2 2016 205

B-Cell Non-Hodgkin Lymphoma - Pipeline by Sutro Biopharma, Inc., H2 2016 206

B-Cell Non-Hodgkin Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016 207

B-Cell Non-Hodgkin Lymphoma - Pipeline by Takara Bio Inc., H2 2016 208

B-Cell Non-Hodgkin Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 209

B-Cell Non-Hodgkin Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2016 210

B-Cell Non-Hodgkin Lymphoma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2016 211

B-Cell Non-Hodgkin Lymphoma - Pipeline by Theravectys SA, H2 2016 212

B-Cell Non-Hodgkin Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016 213

B-Cell Non-Hodgkin Lymphoma - Pipeline by Transgene SA, H2 2016 214

B-Cell Non-Hodgkin Lymphoma - Pipeline by United BioPharma, Inc., H2 2016 215

B-Cell Non-Hodgkin Lymphoma - Pipeline by Unum Therapeutics, Inc., H2 2016 216

B-Cell Non-Hodgkin Lymphoma - Pipeline by Vivolux AB, H2 2016 217

B-Cell Non-Hodgkin Lymphoma - Pipeline by Xenetic Biosciences (UK) Limited, H2 2016 218

Assessment by Monotherapy Products, H2 2016 219

Assessment by Combination Products, H2 2016 220

Number of Products by Stage and Target, H2 2016 222

Number of Products by Stage and Mechanism of Action, H2 2016 239

Number of Products by Stage and Route of Administration, H2 2016 254

Number of Products by Stage and Molecule Type, H2 2016 256

B-Cell Non-Hodgkin Lymphoma - Dormant Projects, H2 2016 1070

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..1), H2 2016 1071

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..2), H2 2016 1072

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..3), H2 2016 1073

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..4), H2 2016 1074

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..5), H2 2016 1075

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..6), H2 2016 1076

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..7), H2 2016 1077

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..8), H2 2016 1078

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..9), H2 2016 1079

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..10), H2 2016 1080

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..11), H2 2016 1081

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..12), H2 2016 1082

B-Cell Non-Hodgkin Lymphoma - Dormant Projects (Contd..13), H2 2016 1083

B-Cell Non-Hodgkin Lymphoma - Discontinued Products, H2 2016 1084

B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..1), H2 2016 1085

B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..2), H2 2016 1086

B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..3), H2 2016 1087

B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..4), H2 2016 1088

B-Cell Non-Hodgkin Lymphoma - Discontinued Products (Contd..5), H2 2016 1089

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

3SBio Inc., AB Science SA, AbbVie Inc, Acetylon Pharmaceuticals, Inc., Actinium Pharmaceuticals, Inc., ADC Therapeutics Sarl, Affimed GmbH, Altor BioScience Corporation, Amgen Inc., arGEN-X BV, Ariad Pharmaceuticals, Inc., Arrien Pharmaceuticals, LLC, Arvinas, Inc., Asana BioSciences, LLC, Astellas Pharma Inc., Astex Pharmaceuticals, Inc., AstraZeneca Plc, Aurigene Discovery Technologies Limited, Bayer AG, BeiGene, Ltd., Bio-Path Holdings, Inc., Biocon Limited, Biogen Inc, Biogenomics Limited, BioInvent International AB, BioNTech AG, Biothera Pharmaceutical Inc, bluebird bio, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Calithera Biosciences, Inc., Celgene Corporation, Cell Medica Limited, Cell>Point, L.L.C., Celldex Therapeutics, Inc., Celltrion, Inc., Cellular Biomedicine Group, Inc., Clevexel Pharma SA, Coherus BioSciences, Inc., Constellation Pharmaceuticals, Inc., Cornerstone Pharmaceuticals, Inc., CrystalGenomics, Inc., CSPC Pharmaceutical Group Limited, CTI BioPharma Corp., Curis, Inc., Cyclacel Pharmaceuticals, Inc., Dynavax Technologies Corporation, eFFECTOR Therapeutics, Inc., Eisai Co., Ltd., Eli Lilly and Company, EpiZyme, Inc., Erytech Pharma SA, Evotec AG, F. Hoffmann-La Roche Ltd., Genentech, Inc., Genor BioPharma Co Ltd, Genosco, Gilead Sciences, Inc., GlaxoSmithKline Plc, H3 Biomedicine Inc., Hutchison MediPharma Limited, IGF Oncology, LLC., Immune Design Corp., ImmunoGen, Inc., Immunomedics, Inc., Immunovaccine, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Inflection Biosciences Limited, Innovent Biologics, Inc., JHL Biotech, Inc., Johnson & Johnson, Juno Therapeutics Inc., Karyopharm Therapeutics, Inc., Kite Pharma Inc, LFB S.A., Mabion SA, mAbxience S.A., MacroGenics, Inc., MedImmune, LLC, Medivation, Inc., MEI Pharma, Inc., Merck & Co., Inc., Merck KGaA, Millennium Pharmaceuticals Inc, Mirati Therapeutics Inc., Molecular Templates Inc., Molplex Ltd., MorphoSys AG, Neumedicines Inc., Nimbus Therapeutics, LLC, Nordic Nanovector ASA, Novartis AG, NovImmune SA, Onconova Therapeutics, Inc., Oncternal Therapeutics, Inc., Ono Pharmaceutical Co., Ltd., OXIS International, Inc., Patrys Limited, Pfizer Inc., Pharmacyclics, Inc., Philogen S.p.A., Portola Pharmaceuticals, Inc., RedHill Biopharma Ltd., Regeneron Pharmaceuticals Inc, Respiratorius AB, Rhizen Pharmaceuticals S.A., Sandoz International GmbH, Sanofi, Seattle Genetics, Inc., Selvita S.A., Shanghai Henlius Biotech Co., Ltd., Sigma-Tau S.p.A., Simcere Pharmaceutical Group, Spectrum Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Sutro Biopharma, Inc., Taiho Pharmaceutical Co., Ltd., Takara Bio Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics, Inc., The International Biotechnology Center (IBC) Generium, Theravectys SA, TRACON Pharmaceuticals Inc, Transgene SA, United BioPharma, Inc., Unum Therapeutics, Inc., Vivolux AB, Xenetic Biosciences (UK) Limited

select a license
Single User License
USD 2500 INR 182250
Site License
USD 5000 INR 364500
Corporate User License
USD 7500 INR 546750

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com